These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 36795304)

  • 1. Correction to: Efficacy of Bacillus Calmette-Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial.
    Sinha S; Ajayababu A; Thukral H; Gupta S; Guha SK; Basu A; Gupta G; Thakur P; Lingaiah R; Das BK; Singh UB; Singh R; Narang R; Bhowmik D; Wig N; Modak DC; Bandyopadhyay B; Chakrabarty B; Kapoor A; Tewari S; Prasad N; Hashim Z; Nath A; Kumari N; Goswami R; Pandey S; Pandey RM
    Infect Dis Ther; 2023 Mar; 12(3):1017-1018. PubMed ID: 36795304
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of Bacillus Calmette-Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial.
    Sinha S; Ajayababu A; Thukral H; Gupta S; Guha SK; Basu A; Gupta G; Thakur P; Lingaiah R; Das BK; Singh UB; Singh R; Narang R; Bhowmik D; Wig N; Modak DC; Bandyopadhyay B; Chakrabarty B; Kapoor A; Tewari S; Prasad N; Hashim Z; Nath A; Kumari N; Goswami R; Pandey S; Pandey RM
    Infect Dis Ther; 2022 Dec; 11(6):2205-2217. PubMed ID: 36242739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland-First Results.
    Czajka H; Zapolnik P; Krzych Ł; Kmiecik W; Stopyra L; Nowakowska A; Jackowska T; Darmochwał-Kolarz D; Szymański H; Radziewicz-Winnicki I; Mazur A
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials.
    Ten Doesschate T; Moorlag SJCFM; van der Vaart TW; Taks E; Debisarun P; Ten Oever J; Bleeker-Rovers CP; Verhagen PB; Lalmohamed A; Ter Heine R; van Crevel R; van de Wijgert J; Janssen AB; Bonten MJ; van Werkhoven CH; Netea MG;
    Trials; 2020 Jun; 21(1):481. PubMed ID: 32503602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
    Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
    Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between presence of Bacillus Calmette-Guerin vaccine scar and coronavirus disease 2019.
    Caliskaner Ozturk B; Vardaloglu I; Ongel Harbiyeli D; Gungordu N; Senkardesler G; Aliyeva N; Ismayilova A; Can G; Balkan II; Gemicioglu B; Borekci S
    Medicine (Baltimore); 2022 Dec; 101(48):e32185. PubMed ID: 36482635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
    Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD
    Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
    Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the role of bacillus calmette-guerin vaccination in protection against COVID-19.
    Chauhan A; Singh M; Agarwal A; Jaiswal N; M Lakshmi PV; Singh M
    Int J Mycobacteriol; 2021; 10(4):433-436. PubMed ID: 34916464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between Bacillus Calmette Guerin Vaccination Policy and Coronavirus Disease-2019 (COVID-19) Incidence.
    Alyasin S; Kanannejad Z; Esmaeilzadeh H; Nabavizadeh H; Ghatee MA; Amin R
    Iran J Allergy Asthma Immunol; 2021 Feb; 20(1):106-113. PubMed ID: 33639625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-target effects of bacillus Calmette-Guérin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19.
    Messina NL; Germano S; McElroy R; Rudraraju R; Bonnici R; Pittet LF; Neeland MR; Nicholson S; Subbarao K; Curtis N;
    Clin Transl Immunology; 2022; 11(4):e1387. PubMed ID: 35573165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
    Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural unblinding of BCG vaccination trials.
    Szigeti R; Kellermayer R
    Vaccine; 2021 Apr; 39(15):2017-2019. PubMed ID: 33744042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of COVID-19 in bacillus Calmette-Guérin vaccinated population.
    Khanum I; Kumar L; Awan S; Jamil B
    Clin Exp Vaccine Res; 2021 Sep; 10(3):276-281. PubMed ID: 34703811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes.
    Faustman DL; Lee A; Hostetter ER; Aristarkhova A; Ng NC; Shpilsky GF; Tran L; Wolfe G; Takahashi H; Dias HF; Braley J; Zheng H; Schoenfeld DA; Kühtreiber WM
    Cell Rep Med; 2022 Sep; 3(9):100728. PubMed ID: 36027906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
    Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
    World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Bacillus Calmette-Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic.
    Yitbarek K; Abraham G; Girma T; Tilahun T; Woldie M
    Vaccine; 2020 Sep; 38(41):6374-6380. PubMed ID: 32798142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guérin immunisation at birth and morbidity among Danish children: A prospective, randomised, clinical trial.
    Thøstesen LM; Nissen TN; Kjærgaard J; Pihl GT; Birk NM; Benn CS; Greisen G; Kofoed PE; Pryds O; Ravn H; Jeppesen DL; Aaby P; Stensballe LG
    Contemp Clin Trials; 2015 May; 42():213-8. PubMed ID: 25896113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis.
    Abubakar I; Pimpin L; Ariti C; Beynon R; Mangtani P; Sterne JA; Fine PE; Smith PG; Lipman M; Elliman D; Watson JM; Drumright LN; Whiting PF; Vynnycky E; Rodrigues LC
    Health Technol Assess; 2013 Sep; 17(37):1-372, v-vi. PubMed ID: 24021245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.